RLYB

RLYB is no longer an operating thesis — it's a merger-arbitrage situation. On March 1, 2026 Rallybio signed a Merger Agreement to combine with Candid (a TCE-autoimmune biotech) alongside a ~$505.5M concurrent financing. The MD&A spells out the math: at a fixed Rallybio valuation of $47.5M (assuming $37.5M net cash) against a $750M Candid valuation, pre-merger Rallybio equityholders are expected to own only ~3.65% of the combined company, with Candid holders at 57.55% and the financing investors at 38.80%. That 3.65% of an implied ~$1.3B combined entity is worth roughly the negotiated $47.5M — i.e. about $8.98 per Rallybio share. The stock at $16.06 ($85M cap) trades ~79% above that deal-implied value, so the closing of the very transaction that is the company's only forward path should compress the price toward ~$9, not lift it.

The standalone business does not support the gap. Revenue is a rounding error ($858K FY2025) and this is a clinical-stage burner: operating income -$33.1M, operating cash flow -$29.8M against just $31.4M of cash. R&D was cut 52.8% YoY and headcount is down to 14 full-time employees — these are cash-conservation moves of a company winding down independent operations, not scaling them. The improved net loss (-$8.98M) and the -87.3% drop in share count (a reverse split) are optical, not signs of a turnaround. The balance sheet is clean (liabilities/equity 0.07x), but $58M of equity sits atop a -$302M accumulated deficit, and the negotiated net-cash mark of $37.5M is what actually backs the exchange ratio.